CHRONOVAC VOYAGEUR: A study of the immune response to yellow fever vaccine among infants previously immunized against measles
- PMID: 28958813
- DOI: 10.1016/j.vaccine.2017.09.047
CHRONOVAC VOYAGEUR: A study of the immune response to yellow fever vaccine among infants previously immunized against measles
Abstract
For administration of multiple live attenuated vaccines, the Advisory Committee on Immunization Practices recommends either simultaneous immunization or period of at least 28days between vaccines, due to a possible reduction in the immune response to either vaccine. The main objective of this study was to compare the immune response to measles (alone or combined with mumps and rubella) and yellow fever vaccines among infants aged 6-24months living in a yellow fever non-endemic country who had receivedmeasles and yellow fever vaccines before travelling to a yellow fever endemic area.
Subjects and methods: A retrospective, multicenter case-control study was carried out in 7 travel clinics in the Paris area from February 1st 2011 to march 31, 2015. Cases were defined as infants immunized with the yellow fever vaccine and with the measles vaccine, either alone or in combination with mumps and rubella vaccine, with a period of 1-27days between each immunization. For each case, two controls were matched based on sex and age: a first control group (control 1) was defined as infants having received the measles vaccine and the yellow fever vaccine simultaneously; a second control group (control 2) was defined as infants who had a period of more than 27days between receiving the measles vaccine and yellow fever vaccine. The primary endpoint of the study was the percentage of infants with protective immunity against yellow fever, measured by the titer of neutralizing antibodies in a venous blood sample.
Results: One hundred and thirty-one infants were included in the study (62 cases, 50 infants in control 1 and 19 infants in control 2). Of these, 127 (96%) were shown to have a protective titer of yellow fever antibodies. All 4 infants without a protective titer of yellow fever antibodies were part of control group 1.
Discussion: The measles vaccine, alone or combined with mumps and rubella vaccines, appears to have no influence on humoral immune response to the yellow fever vaccine when administered between 1 and 27days. The absence of protective antibodies against yellow fever was observed only among infants who received both vaccines simultaneously.
Conclusion: These results may support a revision of current vaccination recommendations concerning the administration of these two live attenuated vaccines either on the same day or at least 28days apart. Our findings show no statistically significant difference if the interval between both vaccines is more than 24 h, but the immune response seems to be reduced when the two vaccines are given at the same time.
Keywords: Administration schedule; Immunization; Measles vaccine; Travelling children; Yellow fever vaccine.
Copyright © 2017 Elsevier Ltd. All rights reserved.
Similar articles
-
Mutual interference on the immune response to yellow fever vaccine and a combined vaccine against measles, mumps and rubella.Vaccine. 2011 Aug 26;29(37):6327-34. doi: 10.1016/j.vaccine.2011.05.019. Epub 2011 Jun 2. Vaccine. 2011. PMID: 21640779 Clinical Trial.
-
Observational study on immune response to yellow fever and measles vaccines in 9 to 15-month old children. Is it necessary to wait 4 weeks between two live attenuated vaccines?Vaccine. 2015 May 11;33(20):2301-6. doi: 10.1016/j.vaccine.2015.03.069. Epub 2015 Apr 2. Vaccine. 2015. PMID: 25843268
-
Use of combination measles, mumps, rubella, and varicella vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP).MMWR Recomm Rep. 2010 May 7;59(RR-3):1-12. MMWR Recomm Rep. 2010. PMID: 20448530
-
A new combination vaccine for measles, mumps, rubella and varicella.Drugs Today (Barc). 2006 May;42(5):321-9. doi: 10.1358/dot.2006.42.5.973586. Drugs Today (Barc). 2006. PMID: 16801995 Review.
-
A combination vaccine against measles, mumps, rubella and varicella.Drugs Today (Barc). 2008 Apr;44(4):279-92. doi: 10.1358/dot.2008.44.4.1210755. Drugs Today (Barc). 2008. PMID: 18536786 Review.
Cited by
-
Yellow fever control: current epidemiology and vaccination strategies.Trop Dis Travel Med Vaccines. 2020 Jan 10;6:1. doi: 10.1186/s40794-020-0101-0. eCollection 2020. Trop Dis Travel Med Vaccines. 2020. PMID: 31938550 Free PMC article. Review.
-
Randomized, double-blinded, controlled non-inferiority trials evaluating the immunogenicity and safety of fractional doses of Yellow Fever vaccines in Kenya and Uganda.Wellcome Open Res. 2019 Nov 20;4:182. doi: 10.12688/wellcomeopenres.15579.1. eCollection 2019. Wellcome Open Res. 2019. PMID: 31984244 Free PMC article.
-
Long-term immunity against yellow fever in children vaccinated during infancy: a longitudinal cohort study.Lancet Infect Dis. 2019 Dec;19(12):1363-1370. doi: 10.1016/S1473-3099(19)30323-8. Epub 2019 Sep 19. Lancet Infect Dis. 2019. PMID: 31543249 Free PMC article.
-
Immunogenicity of yellow fever vaccine co-administered with 13-valent pneumococcal conjugate vaccine in rural Gambia: A cluster-randomised trial.Vaccine. 2025 Feb 15;47:126712. doi: 10.1016/j.vaccine.2025.126712. Epub 2025 Jan 10. Vaccine. 2025. PMID: 39798436 Free PMC article. Clinical Trial.
-
Yellow Fever: Origin, Epidemiology, Preventive Strategies and Future Prospects.Vaccines (Basel). 2022 Feb 27;10(3):372. doi: 10.3390/vaccines10030372. Vaccines (Basel). 2022. PMID: 35335004 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical